San Francisco Bay Area · California
Bay Area device companies tend to move quickly from clinical need to prototype to venture financing. A patent program that keeps pace with that schedule, and holds up when an acquirer reviews it, is worth planning early.
Much of the Bay Area's device culture grew from surgeons who invented. Thomas J. Fogarty, a cardiovascular surgeon who spent 14 years on the Stanford faculty and patented his balloon embolectomy catheter in 1969, later founded Fogarty Innovation, a nonprofit educational incubator on the El Camino Health campus in Mountain View. Stanford's biodesign program, co-founded by Josh Makower, became the Stanford Mussallem Center for Biodesign in 2024 and continues to train innovators to start from carefully defined clinical needs.
The companies that have emerged range from capital equipment to wearables. Intuitive, the robotic-assisted surgery company, is headquartered in Sunnyvale. Shockwave Medical, a Santa Clara developer of intravascular lithotripsy for calcified arterial disease, was acquired by Johnson & Johnson in 2024 in a transaction valued at roughly $13.1 billion. iRhythm, headquartered in San Francisco, is known for its Zio wearable ECG monitors.
In San Francisco, the UCSF Rosenman Institute, founded jointly by QB3 and UCSF's Department of Surgery and Department of Bioengineering and Therapeutic Sciences, helps faculty and outside entrepreneurs move device concepts toward products. California Life Sciences, the statewide life sciences association, is headquartered in South San Francisco.
That environment puts particular pressure on timing and on diligence. Needs-driven programs, demo days, and investor meetings all create opportunities for public disclosure before an application is on file; the United States offers a limited one-year grace period, but many other countries require filing before any disclosure. Venture-backed companies should expect a buyer, as in a platform acquisition like Shockwave, to read the claims against both the product and the competitive field, so claim scope that tracks the commercial embodiment matters more than claim count. Inventions arising at Stanford or UCSF bring license terms, field-of-use limits, and faculty obligations that should be mapped early. And for sensor-plus-software products, claims should rest on how the device acquires and processes signals, not on abstract data analysis alone.
Patent Strategy Considerations
Demo days, conference talks, and publications can start statutory clocks or destroy foreign rights. A well-drafted provisional application filed first preserves options.
Acquirers examine whether claims cover the commercial product and what competitors can do around them. Aligning continuation filings with the product roadmap supports that review.
Stanford and UCSF licenses define what the company controls. Review field of use, sublicensing, and ownership of improvements before relying on the portfolio in a financing.
How Engagements Work
Knechtel Law Group is based in Carefree, Arizona. Patent prosecution and counseling before the U.S. Patent and Trademark Office is federal practice, and engagements with San Francisco Bay Area-area companies are handled directly by senior counsel by video and in person as needed. Matters that turn on state law may call for local counsel.
Request a Confidential ConsultationCommon Questions
No. USPTO practice is federal, and a registered patent attorney may represent applicants anywhere in the United States. Knechtel Law Group is based in Carefree, Arizona. California-law issues, such as employee invention agreements, or litigation in a California court may call for counsel admitted in California.
A provisional can establish an early filing date at modest cost, but it only protects what it actually discloses. A thin provisional may not support the claims you later need, so describe the device, its variations, and how it works in real detail.
Consider claiming the combination of hardware, signal acquisition, and processing steps that produce a technical result, alongside narrower claims on specific algorithms. That approach tends to address subject-matter eligibility concerns more effectively than claiming data analysis in the abstract.
Discuss Your Portfolio
Schedule a confidential consultation to discuss your technology, your existing portfolio, and your plans.
Request a Confidential Consultation